Deep EigenMatics Receives US Patent for AI-Driven Protein Design Method in Drug Discovery
核心洞察
Deep EigenMatics (搜索) has been awarded US Patent 12,424,300 B1 for a two-headed neural network method that jointly generates protein sequence and structure for drug discovery applications.
The breakthrough addresses limitations of existing AI methods that focus only on predicting structure from sequence, potentially missing promising drug candidates for various diseases.
Founded in February 2025, the company has filed 15 US patent applications with four receiving formal Notices of Allowance from the USPTO.
Deep EigenMatics (搜索), a startup focused on artificial intelligence-driven drug discovery, has received a United States patent for a breakthrough method that simultaneously generates protein sequences and structures for therapeutic development. The company was awarded US Patent 12,424,300 B1 for its innovative two-headed neural network approach, marking a significant advancement in AI-based drug discovery technology.
Revolutionary Approach to Protein Design
The patented method represents a departure from conventional AI approaches in drug discovery. Traditional methods have primarily focused on predicting protein structure from amino acid sequences, but Deep EigenMatics (搜索)' innovation jointly generates both sequence and structure given specific conditions such as target receptors. This dual approach addresses a critical gap in existing methodologies that may overlook promising drug candidates.
"This is a significant breakthrough because proteins are characterized by both their sequence of amino acids as well as by their structure, and these together determine protein function," the company stated. The technology enables the generation of a broader range of candidate ligands that can be developed as effective drugs for various diseases.
Strong Intellectual Property Portfolio
Since its founding in February 2025, Deep EigenMatics (搜索) has rapidly built what it describes as one of the strongest intellectual property portfolios in the AI drug discovery space. The company has filed 15 US patent applications for breakthrough inventions, with four already receiving formal Notices of Allowance from the United States Patent and Trademark Office.
The inventor and company founder, Dr. Stephen G. Odaibo, brings a unique interdisciplinary background as an AI expert, mathematician, computer scientist, biochemist, software engineer, and practicing physician. His experience includes two years in the Lefkowitz Lab, working with Dr. Robert J. Lefkowitz, who won the 2012 Nobel Prize in Chemistry for elucidating G-Protein Coupled Receptors (搜索) as drug therapy targets.
Addressing Industry Challenges
Dr. Odaibo highlighted the significant challenges facing current drug development processes. "The drug discovery process is too lengthy, too expensive, and too inefficient, costing on average $2.6 Billion and 10 to 15 years to get a single drug to market," he stated. Despite $300 billion spent worldwide annually on pharmaceutical research, he noted that results remain unsatisfactory while patients continue to suffer.
The company's approach aims to address what Odaibo identifies as oversimplifications in current AI methods that fail to adequately account for the actual biology of cellular function. "Our uniquely integrated interdisciplinary approach at Deep EigenMatics (搜索) addresses this critical gap in the AI-based Drug Discovery field," he explained.
Therapeutic Applications and Partnerships
Deep EigenMatics (搜索) has initiated use of its proprietary Deep Discovery™ (搜索) platform to generate candidate peptide and small molecule drug ligands across five therapeutic areas: Cardiovascular-Renal-Metabolic, Oncology, Immunology, Neurology, and Ophthalmology. The company is currently in early-stage discussions with large pharmaceutical companies regarding potential licensing and co-development partnership agreements.
The company is also extending its intellectual property portfolio worldwide while continuing to innovate with the stated goal of becoming the first company to fully achieve the promise of using AI to discover and prove cures for diseases. Deep EigenMatics (搜索) expects its breakthrough innovations to yield positive high-impact results in future clinical trials.